Gene-expression profiling and the future of adjuvant therapy

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Gene-expression profiling is crucial for distinguishing breast cancer patient risk and guiding adjuvant therapy.
• The Netherlands Cancer Institute developed a 25,000-gene microarray platform for breast cancer research.
• Identifying prognostic and predictive biomarkers is essential for personalized cancer treatment.

Purpose of the Study:

• To identify a prognostic gene-expression classifier for breast cancer risk stratification.
• To explore the potential of gene profiling in predicting patient response to specific adjuvant therapies.
• To accelerate the discovery of predictive biomarkers through neoadjuvant clinical trials.

Main Methods:

• Utilized supervised classification on a 25,000-gene microarray dataset.
• Developed a 70-gene prognostic classifier for breast cancer.
• Planned and initiated neoadjuvant studies to assess gene profiling for predicting therapeutic response.

Main Results:

• A 70-gene prognostic classifier was identified, capable of distinguishing high-risk from low-risk patients.
• Gene profiling shows promise in predicting response to systemic therapies like docetaxel and paclitaxel.
• Neoadjuvant trials are underway to validate gene expression's predictive role in breast cancer treatment.

Conclusions:

• Gene-expression profiling offers valuable prognostic information for breast cancer patients.
• This technology can identify patients likely to benefit from specific adjuvant interventions.
• Future advancements in prognostic and predictive tests will significantly guide breast cancer treatment.